PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data
Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease
Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield
Objective: To estimate SHH responsiveness & signaling of Floor Plate Cells (FPCs) derived from LRRK2 I1371V PD patient-iPSCs along with its link with LRRK2 I1371V…Artificial Intelligence to detect and classify tremors in patients with Parkinson’s disease and related conditions
Objective: To develop a machine learning program to detect and classify tremors in patients with Parkinson's disease (PD) and related conditions. Background: PD is the…SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson’s disease progression
Objective: This study can provide an important insight for identification and prediction of long term neurological sequelae of SARS-CoV-2 infection and proper clinical management the…Dopaminergic Neuronal attributes in aging Substantia Nigra and Ventral Tegmental Area of mice strains distinctly sensitive to MPTP
Objective: To determine the age-related changes in neuronal morphology in the substantia nigra pars compacta (SNpc) and Ventral Tegmental Area (VTA) of C57BL/6J and CD-1…Identification and functional characterization of genetic modifier of penetrance in G2019S LRRK2-associated Parkinson’s disease through family whole genome sequencing
Objective: Trait- or disease-associated genetic variants contribute to substantial variability and penetrance of complex traits and diseases in humans. Several causative genes and risk factors…miR-218-5p Regulates Microglia-mediated Neuroinflammation through Type I Interferon Response in Parkinson’s Disease
Objective: To explore the effect of miR-218-5p on microglia activation and dopaminergic neurons damage in mice model of Parkinson's disease(PD) and its potential mechanisms. Background:…DUtch PARkinson Cohort (DUPARC): Contrast Sensitivity and Retinal Changes in Early Parkinson’s Disease Patients
Objective: To identify and characterize the correlation between static contrast sensitivity (SCS), dynamic contrast sensitivity (DCS), and thickness of the internal plexiform layer (IPL) in…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »